OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/08/26	JP¥20.00	0.00%	161,589,100
12/08/26	JP¥20.00	+5.26%	212,836,000
10/08/26	JP¥19.00	-5.00%	173,539,100
07/08/26	JP¥20.00	0.00%	192,326,800
06/08/26	JP¥20.00	0.00%	190,025,000

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed Japan Exchange 03:30:00 13/08/2026 BST			5-day change	1st Jan Change
20.00 ^JPY	0.00%		0.00%	-

23/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
27/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI

Market Cap	8.16B 51.27M 44.42M 41.62M 37.96M 71.37M 4.89B 72.47M 490M 191M 2.45B 193M 188M	P/E 2025	-8.97x	P/E 2026	-7.57x
Enterprise Value	6.08B 38.15M 33.06M 30.97M 28.25M 53.11M 3.64B 53.93M 364M 142M 1.82B 143M 140M	EV / Sales 2025	9.03x	EV / Sales 2026	7.39x
Free-Float	88.54%	Yield 2025 *	-	Yield 2026	-

23/06/25	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
27/04/25	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI
09/04/25	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding	CI
29/04/24	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
21/04/24	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI
04/04/24	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	CI
18/09/23	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	CI
12/05/23	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
09/04/23	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	CI
23/03/23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	CI
27/04/21	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
11/04/21	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
14/01/19	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	CI

14/05/24	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
05/12/23	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
13/09/22	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer	PU
01/10/20	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine	AQ

OncoTherapy Science, Inc. Share Price

Stocks

4564

JP3202150003

Biotechnology & Medical Research

Valuation: OncoTherapy Science, Inc.

Chart: OncoTherapy Science, Inc.

Latest news : OncoTherapy Science, Inc.

Press Releases: OncoTherapy Science, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: OncoTherapy Science, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	19	20
1 month	19	21
Current year	18	34
1 year	18	34
3 years	15	64
5 years	15	94
10 years	15	338

Manager	Title	Age	Since
Junichi Shimada PSD	President	65	30/06/2022
Zehyon Paku PSD	President	50	04/12/2019
Yuka Yamane CTO	Chief Tech/Sci/R&D Officer	53	31/07/2012

Director	Title	Age	Since
Yuichi Komine BRD	Director/Board Member	54	31/08/2014
Zehyon Paku BRD	Director/Board Member	50	31/05/2018
Hatsuo Kato CHM	Chairman	82	31/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOTHERAPY SCIENCE, INC.	0.00%	0.00%	-25.93%	-35.48%	48.7M
WUXI APPTEC CO., LTD.	-0.73%	+7.82%	+73.81%	+102.34%	70.51B
ARGENX SE	+1.60%	+1.66%	+37.76%	+67.36%	54.05B
INSMED INCORPORATED	-0.22%	+33.59%	+8.43%	+489.75%	28.95B
WUXI BIOLOGICS (CAYMAN) INC.	-0.53%	+9.71%	+47.40%	+6.70%	24.05B
BIONTECH SE	-0.06%	+0.61%	-16.45%	-13.26%	23.31B
PHARMAESSENTIA CORPORATION	-1.37%	+7.87%	+251.71%	+464.53%	18.67B
GENMAB A/S	+2.21%	+7.66%	+47.18%	-20.09%	18.37B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.19%	+3.84%	+26.08%	+622.60%	16.1B
EXELIXIS, INC.	-1.85%	-11.15%	+32.75%	+134.11%	12.72B
Average	-0.13%	+7.72%	+48.28%	+181.86%	26.68B
Weighted average by Cap.	-0.00%	+9.58%	+54.90%	+168.37%

	2025	2026
Net sales	750M 4.71M 4.08M 3.82M 3.49M 6.56M 449M 6.66M 44.97M 17.58M 225M 17.68M 17.3M	808M 5.07M 4.4M 4.12M 3.76M 7.06M 484M 7.17M 48.44M 18.94M 242M 19.05M 18.64M
Net income	-815M -5.12M -4.43M -4.15M -3.79M -7.12M -488M -7.23M -48.86M -19.1M -244M -19.22M -18.8M	-910M -5.71M -4.95M -4.64M -4.23M -7.95M -545M -8.08M -54.56M -21.33M -273M -21.46M -20.99M
Net Debt	-833M -5.23M -4.53M -4.25M -3.87M -7.28M -499M -7.39M -49.94M -19.52M -250M -19.64M -19.21M	-2.09B -13.12M -11.37M -10.65M -9.71M -18.26M -1.25B -18.54M -125M -48.96M -626M -49.25M -48.18M

Current month	+5.26%
3 months	-4.76%
6 months	-4.76%